ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC) is in the highlights and many would want to know whether now might be a good time for it to present much upside. Now trading with a market value of 10.52M, the company has a mix of catalysts and obstacles that spring from the nature of its operations. In light of the many issues surrounding this company, we thought it was a good time to take a close look at the numbers in order to form a realistic perspective on the fundamental picture for this stock.ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC) Fundamentals That Matter
It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For IMUC, the company currently has 4.56 million of cash on the books. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 5.16 million in total assets, balanced by 1.49 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.
ImmunoCellular Therapeutics, Ltd. (IMUC) saw -1.6 million in free cash flow last quarter, representing a quarterly net change in cash of -1.6 million. Perhaps most importantly where cash movements are concerned, the company saw about -1.6 million in net operating cash flow.
But what about the bottom line? After all, that’s what really matters in the end. ImmunoCellular Therapeutics, Ltd. (IMUC) is intriguing when broken down to its core data. The cost of selling goods last quarter was 106, yielding a gross basic income of -106 . For shareholders, given the total diluted outstanding shares of 41.91 million, this means overall earnings per share of -0.02.